SAMUEL REALISTA: Open Payments
NPI 1194052811 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,676 in 17 payments from 11 companies in 2025. Trend: 2023 $207 · 2024 $729 · 2025 $1,676
Food & beverage: $1,676
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 2 | $259 |
| ABIOMED | 2 | $229 |
| Novo Nordisk Inc | 2 | $228 |
| GENZYME CORPORATION | 2 | $152 |
| Medtronic, Inc. | 1 | $146 |
| AstraZeneca Pharmaceuticals LP | 1 | $132 |
| Neurocrine BioSciences, Inc. | 1 | $125 |
| Amgen Inc. | 1 | $117 |
| Axsome Therapeutics, Inc. | 1 | $117 |
| Teva Pharmaceuticals USA, Inc. | 1 | $100 |
Products named: SYMPLICITY G3, BREZTRI, Livdelzi, Epclusa, INGREZZA, Wegovy, REPATHA, Auvelity.
Industry payments across FL — which companies pay providers there.
